key: cord-0810967-i01fwu59 authors: Sud, Maneesh; Qui, Feng; Shah, Rajan; Lee, Douglas S; Nallamothu, Brahmajee K; Natarajan, Madhu K; Wijeysundera, Harindra C; Ko, Dennis T title: Rate of COVID-19 infection in patients with ST-segment elevation myocardial infarction date: 2021-05-21 journal: CJC Open DOI: 10.1016/j.cjco.2021.05.012 sha: 52a33fa5b3e0a461e7614d08ae5897fba7996d5c doc_id: 810967 cord_uid: i01fwu59 BACKGROUND: The incidence of Coronavirus disease 2019 (COVID-19) in patients with ST-segment elevation myocardial infarction (STEMI) has not been fully described. METHODS: All patients with STEMI undergoing primary percutaneous coronary intervention (PCI) in Ontario, Canada between March 1st and September 30th, 2020 were included. Rates of positive COVID-19 tests from January 1(st), 2020 to the date of STEMI were ascertained. For comparison, COVID-19 results were also evaluated in the adult Ontario population between January 1(st), 2020 to September 30(th), 2020 using provincial laboratory testing data. RESULTS: There were 3,606 unique patients presenting with STEMI and receiving PCI in Ontario, Canada during the study period. Sixteen patients (0.44%) tested positive for COVID-19. The background infection rate among all 12,448,541 Ontario residents was similar at 0.34%. CONCLUSIONS: The results of this population-based analysis suggest that proceeding with primary PCI with appropriate infection control practices is reasonable when community infection rates are low. Maneesh Sud MD 1,2,3,4 , Feng Qui MSc 3 , Rajan Shah BSc 3 , Douglas S Lee MD PhD, 2,3,4,5 Brahmajee K Nallamothu MD MPH 6 3, 4 Yet to the best of our knowledge, the incidence of COVID-19 in patients with STEMI has not been fully described in an unselected population. Since this information would be essential for making informed decisions on rethinking strategies to manage STEMI as most countries are battling subsequent waves of the pandemic, our objective was to determine the incidence of COVID-19 in patients presenting to hospital with STEMI. To put these results into perspective, we also compared it with the incidence of COVID-19 in the general population in Ontario, Canada. We linked clinical, laboratory and administrative databases at ICES We identified 3,606 unique STEMI patients presenting in Ontario during the COVID-19 pandemic from March 1st and September 30th, 2020. The mean age was 63 years (standard deviation 12 years) and 72.1% were male. There were 1,535 (42.6%) patients who had COVID-19 testing before or within 7 days after STEMI presentation. Sixteen (0.44%) patients tested positive for COVID-19. Of these, 9 patients (0.25%) tested positive before STEMI and 7 patients (0.19%) tested positive within 7 days after STEMI presentation. The test positivity rate in the STEMI population was 1.0%. Among all 12,448,541 Ontario residents, the age-sex adjusted COVID-19 infection rate was 0.34% and the test positivity was 2.2%. 8 In our study that examined an unselected cohort of STEMI patients during the pandemic in Ontario, we found that the incidence of COVID-19 infection was low compared with conventional knowledge and was only slightly higher than in the general population. To date, only two other studies reported higher COVID-19 rates in STEMI patients at 6.0% from Poland and at 3.7% from Belgium. 5, 6 In addition to the lack of information regarding what proportion of the general population was infected at the time, several important differences should be noted. In the Polish study, patients with either confirmed or suspected COVID-19 were included, which might have led to an artificially higher infection rate. 6 In the Belgium study, data were not available from 27% of the interventional centers. 5 Several potential limitations should be noted. Since patients with STEMI were not routinely tested for COVID-19 in Ontario, it is conceivable that we may have underestimated its true incidence. However, when we extended the testing window and examined COVID-19 results from the index event to October 31 st , very few patients (< 6) were later diagnosed. It is possible that patients with severe illness from COVID-19 and had STEMI were not treated with PCI. However, Ontario has maintained policies to perform primary PCI without changes to routine care in practice and we believe that rarely occurred in our study period. We were not be able to capture STEMI patients with COVID-19 who may have died without reaching the hospital for definitive care. Finally, these findings may not be 9 generalizable to other areas with substantially different community prevalence rates of COVID-19. In summary, although there have been substantial concerns that a high proportion of STEMI patients are infected with COVID 19 leading to recommendations of changes in STEMI systems of care, we found the overall incidence of COVID-19 in patients presenting with STEMI is low and similar or slightly higher than general population. This study provides new insight into the appropriate precautions necessary in managing STEMI patients undergoing primary PCI and suggest it is reasonable to proceed with emergent PCI when community infection rates are low within the framework of appropriate infection control practices and personal protective equipment. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). ICES is an independent, non-profit research institute. Its legal status under Ontario's health information privacy law allows it to collect and analyze health care and demographic data, without consent, for health system evaluation and improvement. The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources. No endorsement by ICES, or the MOHLTC is intended or should be inferred. This study was also supported by the Ontario Health Data Platform (OHDP), a Province of Ontario initiative to support Ontario's ongoing response to COVID-19 and its related impacts. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by the OHDP, its partners, or the Province of Ontario is intended or should be inferred. The authors acknowledge that the clinical registry data used in this publication is from participating hospitals through CorHealth Ontario, which serves as an advisory body to the MOHLTC, is funded by the MOHLTC, and is dedicated to improving the quality, efficiency, access and equity in the delivery of the continuum of adult cardiac, vascular and stroke services in Ontario, Canada. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) ST-Segment Elevation in Patients with Covid-19 -A Case Series American Heart Association's Mission L, Get With The Guidelines Coronary Artery Disease Advisory Work G, the Council on Clinical Cardiology's Committees on Acute Cardiac C, General C, Interventional Cardiovascular C. Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic: AHA's Mission: Lifeline ST-Segment-Elevation Myocardial Infarction Care and COVID-19: The Value Proposition of Fibrinolytic Therapy and the Pharmacoinvasive Strategy Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study Clinical and procedural characteristics of COVID-19 patients treated with percutaneous coronary interventions Parts of this material are based on data and/or information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed in the material are those of the author(s), and not necessarily those of CIHI.